Development and Validation of a Tumour Oxygenation Monitoring Probe
1 other identifier
observational
20
1 country
1
Brief Summary
Laboratory based study in which novel tissue oxygenation probe with the potential provide novel means for assessing response to cancer treatment will be developed and validated.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at below P25 for all trials
Started Aug 2019
Shorter than P25 for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
May 22, 2019
CompletedFirst Posted
Study publicly available on registry
June 11, 2019
CompletedStudy Start
First participant enrolled
August 9, 2019
CompletedPrimary Completion
Last participant's last visit for primary outcome
June 30, 2020
CompletedStudy Completion
Last participant's last visit for all outcomes
June 30, 2020
CompletedResults Posted
Study results publicly available
September 19, 2024
CompletedSeptember 19, 2024
April 1, 2024
11 months
May 22, 2019
January 31, 2022
April 25, 2024
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Count of MRIs Successfully Modelled for Oxygen Correlation
Number of MRIs 3D modelled for oxygenation sensor development Note: this outcome measure was orginally expressed as "Oxygenation Correlation" though this was modeled and therefore we have expressed it as above
MRIs were 3D modelled - single time point at time of MRI
Study Arms (2)
Breast Cancer
Anonymised MRI scans (pre-therapy) of locally advanced breast cancer sufferers.
Rectal Cancer
Anonymised MRI scans (pre-therapy) of locally advanced rectal cancer sufferers.
Interventions
The Oxygenation measurements of the novel diffuse reflectance spectroscopy probe
Eligibility Criteria
Pretreatment anonymised MRIs from (locally advanced) breast and rectal cancer sufferers
You may qualify if:
- MRIs from Breast or Rectal Cancer patients (10 of each)
- Locally advanced Cancers (Stage 2 or 3)
- Patients who went on to receive neoadjuvant chemoradiotherapy.
- Anonymised scans
You may not qualify if:
- MRIs from patients under the age of 18, or older than 99 years old will be excluded.
- MRIs from patients who did not receive neoadjuvant therapy for cancer will be excluded.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Imperial College London
London, Greater London, W21NY, United Kingdom
MeSH Terms
Conditions
Results Point of Contact
- Title
- Dr SImon Dryden
- Organization
- IMperial COllege London
Study Officials
- PRINCIPAL INVESTIGATOR
Ara Darzi
Imperial College London
Publication Agreements
- PI is Sponsor Employee
- Yes
Study Design
- Study Type
- observational
- Observational Model
- OTHER
- Time Perspective
- RETROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
May 22, 2019
First Posted
June 11, 2019
Study Start
August 9, 2019
Primary Completion
June 30, 2020
Study Completion
June 30, 2020
Last Updated
September 19, 2024
Results First Posted
September 19, 2024
Record last verified: 2024-04
Data Sharing
- IPD Sharing
- Will not share
The anonymised scans will be used for this study alone. The participant identifiable data will not be available to our research team, and the scan data will not be made available outside of the research team.